Your comments logical and thanks for making me at least feel a little easier about this stuff up, but…
Long term stability of the key protein in the VitroGro compound surely cannot be the issue. If I recall correctly the company had in store some millions worth of product in readiness to sell into the market when they first expected CE mark approval three years ago. This product had been retained ever since as the Company kept it again in readiness for the next time approval was hopefully gained. I think we were advised the long term stability of the compounds were not regarded as an issue - that is why they kept its value on the books. However if I recall correctly this product was binned only some short time ago but more because it would cost more to update the labels than replace the holding with a fresh batch. I am quite happy to be corrected on any of this of course as I have tended to bottom drawer my holding in this botched company and so it has all just become of passing interest for me.
Thus my thinking on this recent failure is more aligned to management competence. They don’t seem to know what they are doing when it comes to regulatory approval. They surely won’t be of the opinion that getting FDA approval will be easier do they? Fraught is a word that comes to mind. But you would have to happy about one aspect of this company – they are always upbeat about their next attempt at an approval somewhere and so capture that multi billion market in skin care – that is whenever they deem to make any sort of comment. I must admit I wonder why the company is so reticent to tell share holders about what is happening – allows one to think that any information would perhaps expose incompetence. I would be pleased to hear that the reasons for failure this time lay elsewhere. And then back to the bottom drawer.
